Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
6-K - MESOBLAST LTD (0001345099) (Filer)
Regulatory Filings
2026-04-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 591.1KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement from Mesoblast Limited providing a quarterly activity report for the quarter ended March 31, 2026. It includes financial highlights such as net revenues, net operating cash spend, and cash balances. It also discusses operational highlights including clinical trial progress and R&D activities. The document contains an Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rule 4.7B. The Appendix 4C includes detailed cash flow statements for operating, investing, and financing activities for the quarter and year to date. The presence of the Appendix 4C cash flow report and the detailed financial data for the quarter indicates this is a comprehensive interim/quarterly financial report rather than a brief earnings release or a simple announcement. The document is about 15,000 characters long, which supports it being a full report rather than a short announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2026
2026-04-29 English
6-K - MESOBLAST LTD (0001345099) (Filer)
Regulatory Filings
2026-04-29 English
Patient Recruitment Target Achieved in CLBP Pivotal Trial 3 pages 265.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Mesoblast Limited about achieving patient recruitment targets in a pivotal Phase 3 clinical trial for a drug candidate. It discusses clinical trial progress, regulatory designations, expected timelines for top-line results, and potential future regulatory filings. There are no financial statements, detailed financial performance data, or comprehensive management analysis. The document is a corporate announcement about clinical trial progress and regulatory milestones rather than a financial report or earnings release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of officer certifications or compliance documents, nor is it a report publication announcement. The content is best classified as a general regulatory announcement about clinical trial progress and regulatory status, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other categories.
2026-04-28 English
6-K - MESOBLAST LTD (0001345099) (Filer)
Regulatory Filings
2026-04-17 English
Notification regarding unquoted securities - MSB 6 pages 18.7KB
Share Issue/Capital Change Classification · 90% confidence The document is an ASX “Appendix 3G” form notifying the issue of unquoted equity securities (employee incentive options) by Mesoblast Limited. This is a share issue/capital change announcement rather than a full report or AGM material. Therefore it falls under Share Issue/Capital Change (SHA).
2026-04-15 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.